Autotaxin promotes the expression of matrix metalloproteinase-3 via activation of the MAPK cascade in human fibrosarcoma HT-1080 cells

Cancer Investigation

Volumn 27, Issue 4, 2009, Pages 384-390

  Haga, Arayo ^a   Nagai, Hiroyukl ^a   Deyashiki, Yoshihiro ^a  

^a Gifu Prefectural Research Institute for Health and Environmental Science   (Japan)

Author keywords

ATX; Lysopld; MAPK; MMP3; NPP2

Indexed keywords

AUTOTAXIN; HISTIDINE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN C FOS; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; STROMELYSIN; ENPP2 PROTEIN, HUMAN; INORGANIC PYROPHOSPHATASE; LYSOPHOSPHOLIPID; MESSENGER RNA; MMP3 PROTEIN, HUMAN; MULTIENZYME COMPLEX; PHOSPHODIESTERASE I; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN;

ARTICLE; CANCER INVASION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; FIBROSARCOMA; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SARCOMA CELL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; FIBROSARCOMA; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LYSOPHOSPHOLIPIDS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 3; MULTIENZYME COMPLEXES; NEOPLASM INVASIVENESS; PHOSPHODIESTERASE I; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYROPHOSPHATASES; RECOMBINANT PROTEINS; RNA, MESSENGER; UP-REGULATION;

EID: 65249179074     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802491469     Document Type: Article

References (63)

1. Ferry, G.; Tellier, E.; Try, A.; Gres, S.; Naime, I.; Simon, M.F.; Rodriguez, M.; Boucher, J.; Tack, I.; Gesta, S.; Chomarat, R; Dieu, M.; Raes, M.; Galizzi, J.P.; Valet, P.; Boutin, J.A.; Saulnier-Blache, J.S. Autotaxin is released from adipocytes, catalyzes lysophos- phatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J. Biol. Chem. 2003, 278,18162-18169.
2. Stracke, M.L.; Liotta, L.A.; Schiffmann, E. The role of autotaxin and other motility stimulating factors in the regulation of tumor cell motility. Symp. Soc. Exp. Biol. 1993, 47,197-214.
3. Nam, S.W.; Clair, T.; Campo, C.K.; Lee, H.Y.; Liotta, L.A.; Stracke, M.L. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 2000, 19, 241-247.
4. Lee, H.Y.; Bae, G.U.; Jung, I.D.; Lee, J.S.; Kim, Y.K.; Noh, S.H.; Stracke, M.L.; Park, C.G.; Lee, H.W.; Han, J.W. Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells. FEBS Lett. 2002, 515, 137-140.
5. Jung, I.D.; Lee, J.; Yun, S.Y; Park, C.G.; Choi, W.S.; Lee, H.W.; Choi, O.H.; Han, J.W.; Lee, H.Y Cdc42 and Rac1 are necessary for autotaxin-induced tumor cell motility in A2058 melanoma cells. FEBS Lett. 2002, 532, 351-356.
6. Song, J.; Clair, T; Noh, J.H.; Eun, J.W.; Ryu, S.Y; Lee, S.N.; Ahn, Y.M.; Kim, S.Y; Lee, S.H.; Park, W.S.; Yoo, N.J.; Lee, J.Y.; Nam, S.W. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, iysophosphatidic acid, utilizing albumin-bound substrate. Biochem. Biophys. Res. Commun. 2005, 337, 967-975.
7. Nam, S.W.; Clair, T; Kim, Y.S.; McMarlin, A.; Schiffmann, E.; Liotta, L.A.; Stracke, M.L. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 2001, 61, 6938- 6944.
8. van Meeteren, L.A.; Ruurs, P.; Stortelers, C; Bouwman, P.; van Rooijen, M.A.; Pradere, J.R; Pettit, T.R.; Wakelam, M.J.; Saulnier- Blache, J.S.; Mummery, C.L.; Moolenaar, W.H.; Jonkers, J. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 2006, 26, 5015- 5022.
9. Umezu-Goto, M.; Kishi, Y; Taira, A.; Hama, K.; Dohmae, N.; Takio, K.; Yamori, T; Mills, G.B.; Inoue, K.; Aoki, J.; Arai, H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by Iysophosphatidic acid production. J. Ceil. Biol. 2002, 158, 227-233.
10. Gerrard, J.M.; Clawson, C.C.; White, J.G. Lysophosphatidic acids: III. Enhancement of neutrophil chemotaxis. Am. J. Pathol. 1980, 700,609-618.
11. Jalink, K.; Moolenaar, W.H.; Van Duijn, B. Lysophosphatidic acid is a chemoattractant for Dictyostelium discoideum amoebae. Proc. Natl. Acad. Sci. USA 1993, 90,1857-1861.
12. Satoh, Y; Ohkawa, R.; Nakamura, K.; Higashi, K.; Kaneko, M.; Yokota, H.; Aoki, J.; Arai, H.; Yuasa, Y; Yatomi, Y. Lysophosphatidic acid protection against apoptosis in the human pre-B-cell line Nalm-6. Eur. J. Haematol. 2007, 78, 510-517.
13. Hu, Y.L; Tee, M.K.; Goetzl, E.J.; Auersperg, N.; Mills, G.B.; Ferrara, N.; Jaffe, R.B. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst. 2001, 93, 762-768.
14. Sako, A.; Kitayama, J.; Shida, D.; Suzuki, R.; Sakai, T; Ohta, H.; Nagawa, H. Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites. J. Surg. Res. 2006, 730,94-101.
15. Xu, Y; Shen, Z.; Wiper, D.W.; Wu, M.; Morton, R.E.; Elson, P.; Kennedy, A.W.; Belinson, J.; Markman, M.; Casey, G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998, 280, 719-723.
16. Seckl, M.J.; Seufferlein, T; Rozengurt, E. Lysophosphatidic acid- depleted serum, hepatocyte growth factor and stem cell growth factor stimulate colony growth of small cell lung cancer cells through a calcium-independent pathway. Cancer Res. 1994,54,6143-6147.
17. Tigyi, G.; Miledi, R. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 phenochromocytoma cells. J. Biol. Chem. 1992, 267,21360-21367.
18. Xu, Y; Gaudette, D.C.; Boynton, J.D.; Frankel, A.; Fang, X.J.; Sharma, A.; Hurteau, J.; Casey, G.; Goodbody A.; Mellors, A. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. 1995, 1, 1223- 1232.
19. Moolenaar, W.H. Bioactive lysophospholipids and their G protein- coupled receptors. Exp Cell Res 1999, 253, 230-238.
20. Wojciak-Stothard, B.; Ridley, A.J. Rho GTPases and the regulation of endothelial permeability. Vascul. Pharmacol. 2002,39,187-199.
21. Ye, X.; Ishii, I.; Kingsbury, M.A.; Chun, J. Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim. Biophys. Acta. 2002, 1585, 108-113.
22. van Leeuwen, F.N.; Giepmans, B.N.; van Meeteren, LA.; Moolenaar, W.H. Lysophosphatidic acid: mitogen and motility factor. Biochem. Soc. Trans. 2003, 31,1209-1212.
23. Radeff-Huang, J.; Seasholtz, T.M.; Matteo, R.G.; Brown, J.H. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J. Cell. Biochem. 2004,92,949-966.
24. Moolenaar, W.H.; van Meeteren, L.A.; Giepmans, B.N. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004,26,870- 881.
25. Saatian, B.; Zhao, Y; He, D.; Georas, S.N.; Watkins, T.; Spannhake, E.W.; Natarajan, V. Transcriptional regulation of Iysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. Biochem. J. 2006, 393, 657-668.
26. Woessner, J.F. Jr. Matrix metalloproteinases and the inhibitors in connective tissue remodeling. FASEB J. 1991, 5,2145-2154.
27. Matrisian, L.M. The matrix-degrading metalloproteinases. Bioas- says 1992, 14, 455-463.
28. Butticè, G.; Duterque-Coquillaud, M.; Basuyaux, J.P.; Carrère, S.; Kurkinen, M.; Stehelin, D. Erg, an Ets-family member, differentially regulates human collagenasel (MMP1)andstromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 1996, 13, 2297-2306.
29. Biondi, M.L.; Turri, O.; Leviti, S.; Seminati, R.; Cecchini, R; Bernini, M.; Ghilardi, G.; Guagnellini, E.; MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin. Chem. 2000, 46, 2023- 2024.
30. Kusukawa, J.; Harada, H.; Shima, I.; Sasaguri, Y; Kameyama, T; Morimatsu, M. The significance of epidermal growth factor receptor and matrix metalloproteinase-3 in squamous ceil carcinoma of the oral cavity. Eur. J. Cancer Oral. Oncol. 1996, 32B, 217-221.
31. Eum, S.-Y; Lee, Y.-W.; Hennig, B.; Toborek, M. Interplay between epidermal growth factor receptor and janus kinase 3 regulates polychlorinated biphenyl-lnduced matrix metalloproteinase-3 expression and transendothelial migration of tumor Cells. Mol. Cancer Res. 2006, 4, 361-370.
32. MacNaul, K.L; Chartrain, N.; Lark, M.; Tocci, M.J.; Hutchinson, N.I. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. J. Biol. Chem. 1990, 265,17238-17245.
33. Behera, A.K.; Thorpe, CM.; Kidder, J.M.; Smith, W.; Hildebrand, E.; Hu, L.T. Borrelia burgdorferi-lnduced expression of matrix metalloproteinases from human chondrocytes requires mitogen- activated protein kinase and janus kinase/signal transducer and activator of transcription signaling pathways. Infect. Immun. 2004, 72,2864-2871.
34. Park, C.-H.; Lee, M.J.; Ahn, J.; Kim, S.; Kim, H.H.; Kim, K.H.; Eun, H.C; Chung, J.H. Heat shock-induced matrix metalloproteinase (MMP)-1 and MMP-3 are mediated through ERK and JNK activation and via an autocrine interleukin-6 loop. J. Invest Dermatol. 2004, 123,1012-1019.
35. Sweeney, S.E.; Hammaker, D.; Boyle, D.L.; Firestein, G.S. Regulation of c-Jun phosphorylation by the IkB kinase-Ecomplex in fibroblast-like synoviocytes. J. Immunol. 2005, 174, 6424-6430.
36. Inoue, T.; Hammaker, D.; Boyle, D.L.; Firestein, G.S. Regulation of JNK by MKK-7 in fibroblast-like synoviocytes. Arthritis Rheum. 2006, 54, 2127-2135.
37. Haga, A.; Hashimoto, K.; Tanaka, N.; Nakamura, K.T.; Deyashiki, Y. Scalable purification and characterization of the extracellular domain of human autotaxin from prokaryotic cells. Protein Expr. Purif.2008, 59, 9-17.
38. van Meeteren, L.A.; Ruurs, P.; Christodoulou, E.; Goding, J.W.; Takakusa, H.; Kikuchi, K.; Perrakis, A.; Nagano, T; Moole- naar, W.H. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J. Biol. Chem. 2005, 280, 21155- 21161.
39. Clair, T; Koh, E.; Ptaszynska, M.; Bandle, R.W.; Liotta, L.A.; Schiff- mann, E.; Stracke, M.L. PMC L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin. Lipids Health Dis. 2005, 5,1-18.
40. Smyth, S.S.; Sciorra, V.A.; Sigal, Y.J.; Pamuklar, Z.; Wang, Z.; Xu, Y; Prestwich, G.D.; Morris, A.J. Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets: studies using chemical inhibitors of lipid phosphate phosphatase activity. J. Biol. Chem. 2003, 278, 43214- 43223.
41. Cui, P.; Tomsig, J.L.; McCalmont, W.F.; Lee, S.; Becker, C.J.; Lynch, K.R.; Macdonald, T.L. Synthesis and biological evaluation of phos- phonate derivatives as autotaxin (ATX) inhibitors. Bioorg. Med. Chem. Lett. 2007, 17,1634-1640.
42. Achterberg, V.; Gercken, G. Metabolism of ether lysophospholipids in Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 1987, 26,277-287.
43. Kawasaki, T.; Snyde, F. The metabolism of lyso-platelet- activating factor (1-0-alkyl-2-lyso-sn-glycero-3-phosphocholine) by a calcium-dependent lysophospholipase D in rabbit kidney medulla. Biochim. Biophys. Acta. 1987, 920, 85-93.
44. Gijsbers, R.; Aoki, J.; Arai, H.; Bollen, M. The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett. 2003, 538, 60-64.
45. Zalatan, J.G.; Fenn, T.D.; Brunger, AT.; Herschlag, D. Structural and functional comparisons of nucleotide pyrophosphatase/phosphodiesterase and alkaline phosphatase: implications for mechanism and evolution. Biochemistry 2006, 45,9788- 9803.
46. Zhao, Y; He, D.; Saatian, B.; Watkins, T; Spannhake, E.W.; Pyne, N.J.; Natarajan, V. Regulation of lysophosphatidic acid-induced epidermal growth factor receptor transactivation and interleukin-8 secretion in human bronchial epithelial cells by protein kinase C,Lyn kinase, and matrix metalloproteinases. J. Biol. Chem. 2006, 281,19501-19511.
47. Deng, T.; Karin, M. c-Fos transcriptional activity stimulated by H- Ras-activated protein kinase distinct from JNK and ERK. Nature 1994, 371, 171-175.
48. Monje, R; Marinissen, M.J.; Gutkind, J.S. Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Mol. Cell. Biol. 2003, 23, 7030-7043.
49. Shah, B.H.; Baukal, A.J.; Shah, F.B.; Catt, K.J. Mechanisms of ex- tracellularly regulated kinases 1/2 activation in adrenal glomeru- losa cells by lysophosphatidic acid and epidermal growth factor. Mol. Endocrinol. 2005, 19, 2535-2548.
50. Nishida, E.; Gotoh, Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem. Sci. 1993, 18,128-131.
51. Ip, Y.T.; Davis, R.J. Signal transduction by the c-Jun N-terminal kinase (JNK)-from unflammation to development. Curr. Opin. Cell. Biol. 1998, 10,205-219.
52. Sambucetti, L.C.; Curren, T. The Fos protein complex is associated with DNA in isolated nuclei and binds to DNA cellulose. Science 1986, 234, 1417-1419.
53. Distel, R.J.; Ro, H.S.; Rosen, B.S.; Groves, D.L; Spiegelman, B.M. Nucleoprotein complexes that regulate gene expression in adipocyte differentiation: direct participation of c-Fos. Cell 1987, 49, 835-844.
54. Bhomann, D.; Bos, T.J.; Admon, A.; Nishimura, T.; Vogt, P.K.; Tjian, R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP- 1. Science 1987, 238,1386-1392.
55. Jeon, E.S.; Song, H.Y.; Kim, M.R.; Moon, H.J.; Bae, Y.C.; Jung, J.S.; Kim, J.H. Sphingosylphosphorylcholine induces proliferation of human adipose tissue-derived mesenchymal stem cells via activation of JNK. J. Lipid Res. 2006, 47, 653-664.
56. Lee, Y.J.; Shukla, S.D. Pro- and anti-apoptotic roles of c-Jun N- terminal kinase (JNK) in ethanol and acetaldehyde exposed rat hepatocytes. Eur. J. Pharmacol. 2005, 31, 31-45.
57. Korhonen, R.; Linker.K.; Pautz, A.; Förstermann, U.; Moilanen, E.; Kleinert, H. Post-transcriptional regulation of human inducible nitric-oxide synthase expression by the Jun N-terminal kinase. Mol. Pharmacol. 2007, 711427-1434.
58. Gaire, M.; Magbanua, Z.; McDonnell, S.; McNeil, L.; Lovett, D.H.; Matrisian, L.M. Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J. Biol. Chem. 1994,269, 2032-2040.
59. Sato, H.; Seiki, M. Regulatory mechanism of 92 kDa type IV col- lagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993, 8, 395-405.
60. Uria, J.A.; Jiménez, M.G.; Balbín, M.; Freije, J.M.; López-Otín, C. Differential effects of transforming growth factor-beta on the expression of collagenase-1 and coIlagenase-3 in human fibroblasts. J. Biol. Chem. 1998, 273, 9769-9777.
61. Stracke, M.L.; Krutzsch, H.C.; Unsworth, E.J.; Arestad, A.; Cioce, V.; Schiffmann, E.; Liotta, L. A. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 1992, 267, 2524-2529.
62. Murata, J.; Lee, H.Y; Clair, T; Krutzsch, H.C.; Arestad, A.A.; Sobel, M.E.; Liotta, L.A.; Stracke, M.L. cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J. Biol. Chem. 1994, 269, 30479-30484.
63. Clair, T.; Lee, H.Y.; Liotta, L.A.; Stracke, M.L. Autotaxin is an exoen- zyme possessing 5'-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities, J. Biol. Chem. 1997, 271, 996- 1001.